A timeline for Parkinson's disease

Parkinsonism and Related Disorders

Volumn 16, Issue 2, 2010, Pages 79-84

  Hawkes, Christopher H ^a   Del Tredici, Kelly ^b   Braak, Heiko ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Department of Neurology   (Germany)

Author keywords

Parkinson's disease; Prodrome; Timeline

Indexed keywords

ALPHA SYNUCLEIN;

CLINICAL FEATURE; CLINICAL OBSERVATION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LEWY BODY; MORTALITY; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SMELLING DISORDER;

DISEASE PROGRESSION; HUMANS; LEWY BODIES; MODELS, BIOLOGICAL; PARKINSON DISEASE;

EID: 75749135592     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2009.08.007     Document Type: Review

References (93)

1. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 (2001) 456-462
2. Abbott R.D., Ross G.W., Petrovitch H., Tanner C.M., Davis D.G., Masaki K.H., et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22 (2007) 1581-1586
3. Abbott R.D., Ross G.W., White L.R., Nelson J.S., Masaki K.H., Tanner C.M., et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 59 (2002) 1051-1057
4. Abbott R.D., Ross G.W., White L.R., Tanner C.M., Masaki K.H., Nelson J.S., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65 (2005) 1442-1446
5. Alonso A., Rodriguez L.A., Logroscino G., and Hernan M.A. Use of antidepressants and the risk of Parkinson's disease: a prospective study. J Neurol Neurosurg Psychiatry 80 (2009) 671-674
6. Aston-Jones G. Brain structures and receptors involved in alertness. Sleep Med 6 Suppl 1. (2005) S3-S7
7. Aston-Jones G., Rajkowski J., and Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog Brain Res 126 (2000) 165-182
8. Ben-Shlomo Y., and Marmot M.G. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?. J Neurol Neurosurg Psychiatry 58 (1995) 293-299
9. Birch J., Kolle R.U., Kunkel M., Paulus W., and Upadhyay P. Acquired colour deficiency in patients with Parkinson's disease. Vis Res 38 (1998) 3421-3426
10. Bosboom J.L., Stoffers D., and Wolters E.C. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111 (2004) 1303-1315
11. Braak H., Bohl J.R., Muller C.M., Rüb U., de Vos R.A., and Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21 (2006) 2042-2051
12. Braak H., de Vos R.A., Bohl J., and Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396 (2006) 67-72
13. Braak H., and Del Tredici K. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered. Exp Neurol 212 (2008) 226-229
14. Braak H., and Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70 (2008) 1916-1925
15. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
16. Braak H., Ghebremedhin E., Rüb U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 (2004) 121-134
17. Burke R.E., Dauer W.T., and Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 64 (2008) 485-491
18. Buzas B., and Max M.B. Pain in Parkinson disease. Neurology 62 (2004) 2156-2157
19. Chateau D., and Aron C.L. Heterotypic sexual behavior in male rats after lesions in different amygdaloid nuclei. Horm Behav 22 (1988) 379-387
20. Chaudhuri K.R., Healy D.G., and Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5 (2006) 235-245
21. Chen H., Zhang S.M., Schwarzschild M.A., Hernan M.A., Willett W.C., and Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol 159 (2004) 547-555
22. D'Amelio M., Ragonese P., Morgante L., Reggio A., Callari G., Salemi G., et al. Long-term survival of Parkinson's disease: a population-based study. J Neurol 253 (2006) 33-37
23. Del Tredici K., and Braak H. A not entirely benign procedure: progression of Parkinson's disease. Acta Neuropathol 115 (2008) 379-384
24. Dickson DW, Uchikado H, Klos KJ, Josephs KA, Boeve BF, Ahlskog J, A critical review of the Braak staging system for Parkinson's disease. 2006.
25. Doty R.L., Deems D.A., and Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38 (1988) 1237-1244
26. Edwards L.L., Quigley E.M., and Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42 (1992) 726-732
27. Elbaz A., Bower J.H., Peterson B.J., Maraganore D.M., McDonnell S.K., Ahlskog J.E., et al. Survival study of parkinson disease in Olmsted County, Minnesota. Arch Neurol 60 (2003) 91-96
28. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 Pt 5 (1991) 2283-2301
29. Fibiger H.C. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 11 (1984) 105-107
30. Fujishiro H., Frigerio R., Burnett M., Klos K.J., Josephs K.A., DelleDonne A., et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 23 (2008) 1085-1092
31. Gao X., Chen H., Schwarzschild M.A., Glasser D.B., Logroscino G., Rimm E.B., et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol 166 (2007) 1446-1450
32. Gonera E.G., van't H.M., Berger H.J., van W.C., and Horstink M.W. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 12 (1997) 871-876
33. Haehner A., Hummel T., Hummel C., Sommer U., Junghanns S., and Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 22 (2007) 839-842
34. Haensch C.A., Lerch H., Jorg J., and Isenmann S. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. Parkinsonism Relat Disord 15 (2009) 134-137
35. Halliday G., Hely M., Reid W., and Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115 (2008) 409-415
36. Halliday G.M., Del Tredici K., and Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl (2006) 99-103
37. Hawkes C.H. Parkinson's disease and aging: same or different process?. Mov Disord 23 (2008) 47-53
38. Hawkes C.H. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it?. Mov Disord (2008)
39. Hawkes C.H., Del Tredici K., and Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33 (2007) 599-614
40. Hawkes C.H., Shephard B.C., and Daniel S.E. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 62 (1997) 436-446
41. Herlofson K., Lie S.A., Arsland D., and Larsen J.P. Mortality and Parkinson disease: a community based study. Neurology 62 (2004) 937-942
42. Hu G., Jousilahti P., Nissinen A., Antikainen R., Kivipelto M., and Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 67 (2006) 1955-1959
43. Ikemura M., Saito Y., Sengoku R., Sakiyama Y., Hatsuta H., Kanemaru K., et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 (2008) 945-953
44. Iranzo A., Molinuevo J.L., Santamaria J., Serradell M., Marti M.J., Valldeoriola F., et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5 (2006) 572-577
45. Ishihara-Paul L., Wainwright N.W., Khaw K.T., Luben R.N., Welch A.A., Day N.E., et al. Prospective association between emotional health and clinical evidence of Parkinson's disease. Eur J Neurol 15 (2008) 1148-1154
46. Iwanaga K., Wakabayashi K., Yoshimoto M., Tomita I., Satoh H., Takashima H., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52 (1999) 1269-1271
47. Jellinger K.A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 106 (2003) 191-201
48. Jellinger K.A. The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci 248 (2006) 167-172
49. Jellinger K.A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116 (2008) 1-16
50. Kalaitzakis M.E., Christian L.M., Moran L.B., Graeber M.B., Pearce R.K., and Gentleman S.M. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 15 (2009) 196-204
51. Kayama Y., and Koyama Y. Control of sleep and wakefulness by brainstem monoaminergic and cholinergic neurons. Acta Neurochir Suppl 87 (2003) 3-6
52. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 17 (1997) 8451-8458
53. Korczyn A.D. Autonomic nervous screening in paitents with early Parkinson's disease. In: Przuntek H., and Riederer P. (Eds). Early diagnosis and preventive therapy in Parkinson's disease (1989), Springer-Verlag, Vienna
54. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., and Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (2008) 504-506
55. Kordower J.H., Chu Y., Hauser R.A., Olanow C.W., and Freeman T.B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 23 (2008) 2303-2306
56. Lebouvier T., Chaumette T., Damier P., Coron E., Touchefeu Y., Vrignaud S., et al. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 57 (2008) 1741-1743
57. Leentjens A.F., Van den Akker M., Metsemakers J.F., Lousberg R., and Verhey F.R. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 18 (2003) 414-418
58. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (2008) 501-503
59. Logroscino G., Sesso H.D., Paffenbarger Jr. R.S., and Lee I.M. Body mass index and risk of Parkinson's disease: a prospective cohort study. Am J Epidemiol 166 (2007) 1186-1190
60. Markesbery W.R., Jicha G.A., Liu H., and Schmitt F.A. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 68 (2009) 816-822
61. Mayeux R., Stern Y., Cote L., and Williams J.B. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34 (1984) 642-646
62. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14 (2008) 507-509
63. Miasnikov A.A., Chen J.C., and Weinberger N.M. Behavioral memory induced by stimulation of the nucleus basalis: effects of contingency reversal. Neurobiol Learn Mem 91 (2009) 298-309
64. Minguez-Castellanos A., Chamorro C.E., Escamilla-Sevilla F., Ortega-Moreno A., Rebollo A.C., Gomez-Rio M., et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? a cohort study. Neurology 68 (2007) 2012-2018
65. Morgante L., Salemi G., Meneghini F., Di Rosa A.E., Epifanio A., Grigoletto F., et al. Parkinson disease survival: a population-based study. Arch Neurol 57 (2000) 507-512
66. Muller C.M., de Vos R.A., Maurage C.A., Thal D.R., Tolnay M., and Braak H. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol 64 (2005) 623-628
67. Muller T., Woitalla D., Peters S., Kohla K., and Przuntek H. Progress of visual dysfunction in Parkinson's disease. Acta Neurol Scand 105 (2002) 256-260
68. Nilsson F.M., Kessing L.V., and Bolwig T.G. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 104 (2001) 380-386
69. Nolano M., Provitera V., Estraneo A., Selim M.M., Caporaso G., Stancanelli A., et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 131 (2008) 1903-1911
70. Orimo S., Takahashi A., Uchihara T., Mori F., Kakita A., Wakabayashi K., et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17 (2007) 24-30
71. Orimo S., Uchihara T., Nakamura A., Mori F., Kakita A., Wakabayashi K., et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 (2008) 642-650
72. Pahapill P.A., and Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 123 Pt 9 (2000) 1767-1783
73. Parkkinen L., Kauppinen T., Pirttila T., Autere J.M., and Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57 (2005) 82-91
74. Parkkinen L., Pirttila T., and Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115 (2008) 399-407
75. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E.C., and Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56 (2004) 173-181
76. Postuma R.B., Gagnon J.F., Vendette M., Charland K., and Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 23 (2008) 1665-1672
77. Probst A., Bloch A., and Tolnay M. New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central?. Eur J Neurol 15 Suppl 1. (2008) 1-4
78. Rodgers R.J., Halford J.C., Nunes de Souza R.L., Canto de Souza A.L., Piper D.C., Arch J.R., et al. Dose-response effects of orexin-A on food intake and the behavioural satiety sequence in rats. Regul Pept 96 (2000) 71-84
79. Ross G.W., Abbott R.D., Petrovitch H., Tanner C.M., Davis D.G., Nelson J., et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21 (2006) 2062-2067
80. Rub U., Del Tredici K., Schultz C., Ghebremedhin E., de Vos R.A., Jansen S.E., et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 23 (2002) 245-254
81. Schenck C.H., Bundlie S.R., and Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46 (1996) 388-393
82. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 23 Suppl 3. (2008) S521-S533
83. Shah M., Deeb J., Fernando M., Noyce A., Visentin E., Findley L.J., et al. Abnormality of taste and smell in Parkinson's disease. Parkinsonism Relat Disord (2008)
84. Shibata M., Morita Y., Shimizu T., Takahashi K., and Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 276 (2009) 79-83
85. Silveira-Moriyama L., Guedes L.C., Kingsbury A., Ayling H., Shaw K., Barbosa E.R., et al. Hyposmia in G2019S LRRK2-related Parkinsonism: clinical and pathologic data. Neurology 71 (2008) 1021-1026
86. Stiasny-Kolster K., Doerr Y., Moller J.C., Hoffken H., Behr T.M., Oertel W.H., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128 (2005) 126-137
87. Sutcliffe J.G., and de L.L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 62 (2000) 161-168
88. Thorpe A.J., Mullett M.A., Wang C., and Kotz C.M. Peptides that regulate food intake: regional, metabolic, and circadian specificity of lateral hypothalamic orexin A feeding stimulation. Am J Physiol Regul Integr Comp Physiol 284 (2003) R1409-R1417
89. Tolosa E., Compta Y., and Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 13 Suppl (2007) S2-S7
90. Verbaan D., Marinus J., Visser M., van Rooden S.M., Stiggelbout A.M., and van Hilten J.J. Patient-reported autonomic symptoms in Parkinson disease. Neurology 69 (2007) 333-341
91. Waseem S., and Gwinn-Hardy K. Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 110 (2001) 33-40 46
92. Weiss F., and Koob G.F. Drug addiction: functional neurotoxicity of the brain reward systems. Neurotox Res 3 (2001) 145-156
93. Yagi H., Akiguchi I., Ohta A., Yagi N., Hosokawa M., and Takeda T. Spontaneous and artificial lesions of magnocellular reticular formation of brainstem deteriorate avoidance learning in senescence-accelerated mouse SAM. Brain Res 791 (1998) 90-98